To this end, combined STAT3 inhibitors such as anti-sense oligonucleotides (AZD9150) [242] are currently undergoing clinical evaluation in combination with anti-PD1 immunotherapies for the treatment of NSCLC (NCT03334617, NCT02983578). Here, PDCD1 is linked to non-small cell lung carcinoma.